APA
Aranda E., García-Alfonso P., Benavides M., Sánchez Ruiz A., Guillén-Ponce C., Safont M. J., Alcaide J., Gómez A., López R., Manzano J. L., Méndez Ureña M., Sastre J., Rivera F., Grávalos C., García T., Martín-Valadés J. I., Falcó E., Navalón M., González Flores E., Ma García Tapiador A., Ma López Muñoz A., Barrajón E., Reboredo M., García Teijido P., Viudez A., Cárdenas N. & Díaz-Rubio E. (20190415). First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. : European journal of cancer (Oxford, England : 1990).
Chicago
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont M J, Alcaide J, Gómez A, López R, Manzano J L, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés J I, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N and Díaz-Rubio E. 20190415. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. : European journal of cancer (Oxford, England : 1990).
Harvard
Aranda E., García-Alfonso P., Benavides M., Sánchez Ruiz A., Guillén-Ponce C., Safont M. J., Alcaide J., Gómez A., López R., Manzano J. L., Méndez Ureña M., Sastre J., Rivera F., Grávalos C., García T., Martín-Valadés J. I., Falcó E., Navalón M., González Flores E., Ma García Tapiador A., Ma López Muñoz A., Barrajón E., Reboredo M., García Teijido P., Viudez A., Cárdenas N. and Díaz-Rubio E. (20190415). First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. : European journal of cancer (Oxford, England : 1990).
MLA
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont M J, Alcaide J, Gómez A, López R, Manzano J L, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés J I, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N and Díaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. : European journal of cancer (Oxford, England : 1990). 20190415.